Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06818643 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
A Phase 1 study of Advanced Solid Tumors and Malignant Neoplasm, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 270
- Enrollment target
- 20
- Study locations
NCT06818643 is a Phase 1 study of Advanced Solid Tumors and Malignant Neoplasm that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 270 participants, above the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (37% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT06818643, a Phase 1 study of Advanced Solid Tumors and Malignant Neoplasm, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 270 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids. The main goal of this study is to learn about the safety of MK-3120 and if people tolerate it.
Conditions Studied
Interventions
- BIOLOGICAL MK-3120
Study Locations (20)
Region M. de Santiago
- Centro de Estudios Clínicos SAGA ( Site 0033) - Santiago
- FALP ( Site 0031) - Santiago
- Pontificia Universidad Catolica de Chile ( Site 0032) - Santiago
- Bradford Hill Centro de Investigaciones Clinicas ( Site 0030) - Santiago
Other
- Rambam Health Care Campus ( Site 0082) - Haifa
- Rabin Medical Center ( Site 0081) - Petah Tikva
- Sheba Medical Center ( Site 0080) - Ramat Gan
Alabama
- The University of Alabama at Birmingham ( Site 1005) - Birmingham
Florida
- University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1003) - Miami
New Jersey
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 1009) - Hackensack
Virginia
- Virginia Commonwealth University ( Site 1008) - Richmond
Beijing Municipality
- Peking University First Hospital ( Site 0180) - Beijing
Chongqing Municipality
- Chongqing Cancer Hospital ( Site 0186) - Chongqing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2025-03-25 |
| Est. Completion | 2031-03-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06818643
The ClinicalTrials.gov registry entry for NCT06818643 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 270 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (37% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which MK-3120 is the first listed.
NCT06818643 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Region M. de Santiago, Other, Alabama.
Frequently Asked Questions
What is clinical trial NCT06818643 about?
NCT06818643 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)". Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids. The main go...
What is the current status of trial NCT06818643?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 270 participants. The study started on 2025-03-25. Estimated completion is 2031-03-25.
What conditions does trial NCT06818643 study?
This clinical trial studies the following conditions: Advanced Solid Tumors, Malignant Neoplasm.
What interventions are being tested in trial NCT06818643?
The interventions under investigation include: MK-3120 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06818643?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06818643 being conducted?
This trial has 20 study locations across Alabama, Florida, New Jersey, Virginia, Region M. de Santiago. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.